Literature DB >> 15277289

The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage.

Sophia Koo1, Nils Kucher, Paul L Nguyen, John Fanikos, Peter W Marks, Samuel Z Goldhaber.   

Abstract

BACKGROUND: We aimed to determine the effect of excessive anticoagulation on morbidity and mortality in hospitalized patients with major anticoagulant-associated hemorrhage.
METHODS: We prospectively identified 101 consecutive inpatients admitted to Brigham and Women's Hospital with major bleeding occurring during administration of warfarin sodium, unfractionated heparin (UFH), or low-molecular-weight heparin (LMWH).
RESULTS: Fifty patients had excessive and 51 had nonexcessive anticoagulation. The overall mortality at 60 days was 26% (13/50) in the excessive group compared with 10% (5/51) in the nonexcessive group (P =.03). Excessive warfarin therapy was associated with an increased 60-day mortality (P =.049), in contrast to excessive anticoagulation with UFH or LMWH alone (P =.27) or UFH or LMWH as a "bridge" to warfarin therapy (P =.10). Multivariate regression identified excessive anticoagulation as an independent predictor of 60-day mortality (adjusted hazard ratio [HR], 4.17; 95% confidence interval [CI], 1.39-12.49; P =.01), along with intracranial hemorrhage (adjusted HR, 6.16; 95% CI, 1.75-21.67; P =.005) and active cancer (adjusted HR, 3.79; 95% CI, 1.13-12.70; P =.03). Excessive anticoagulation was also a significant predictor of the combined nonfatal end point of stroke, myocardial infarction, hypotension, critical anemia, and surgical or angiographic intervention at 30 days (HR, 2.17; 95% CI, 1.25-3.78; P =.006).
CONCLUSION: In a cohort of patients with anticoagulation-associated hemorrhage, excessive anticoagulation contributed independently to increased morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277289     DOI: 10.1001/archinte.164.14.1557

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

Review 1.  Managing anticoagulant related coagulopathy.

Authors:  Amir K Jaffer
Journal:  J Thromb Thrombolysis       Date:  2007-10-17       Impact factor: 2.300

Review 2.  Oral anticoagulant-associated intracerebral hemorrhage.

Authors:  Alvaro Cervera; Sergio Amaro; Angel Chamorro
Journal:  J Neurol       Date:  2011-07-05       Impact factor: 4.849

3.  Teaching improves adherence to clinical guidelines in the treatment of oral anticoagulation-related severe bleeding in the emergency department.

Authors:  Benjamin Tremey; Karim Tazarourte; Catherine Ract; Mahjoub Gabteni; Leila Lavagna; Jacqueline Dépret-Vassal; Valérie Ségalin; Stéphane Saintonge; Bernard Vigué
Journal:  Intensive Care Med       Date:  2009-04-04       Impact factor: 17.440

4.  Reduced Z-axis coverage multidetector CT angiography for suspected acute pulmonary embolism could decrease dose and maintain diagnostic accuracy.

Authors:  Joshua A Kallen; Bret F Coughlin; Michael T O'Loughlin; Barry Stein
Journal:  Emerg Radiol       Date:  2009-05-26

5.  Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin.

Authors:  Fatemeh Saheb Sharif-Askari; Syed Azhar Syed Sulaiman; Narjes Saheb Sharif-Askari; Ali Al Sayed Hussain; Mohammad Jaffar Railey
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

6.  Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation-The EWA study.

Authors:  Samuli Jaakkola; Ilpo Nuotio; Tuomas O Kiviniemi; Raine Virtanen; Melina Issakoff; K E Juhani Airaksinen
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

7.  Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance.

Authors:  Nancy El-Helou; Amal Al-Hajje; Rola Ajrouche; Sanaa Awada; Samar Rachidi; Salam Zein; Pascale Salameh
Journal:  Vasc Health Risk Manag       Date:  2013-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.